ICU Medical Inc (NASDAQ:ICUI) reported its fourth-quarter 2025 financial results after the market close on Wednesday, February 19, 2026. The medical device manufacturer delivered a mixed performance, beating analyst expectations on profitability while seeing a significant year-over-year decline in revenue. The company also provided its initial financial guidance for the 2026 fiscal year.
Fourth Quarter Performance vs. Estimates
For the quarter ended December 31, 2025, ICU Medical reported revenue of $540.7 million. This figure represents a 14.1% decrease compared to the $629.8 million generated in the fourth quarter of 2024. However, it narrowly surpassed the analyst consensus estimate of approximately $541.2 million.
The company’s performance on the bottom line was more positive relative to expectations. ICU Medical posted a non-GAAP adjusted earnings per share (EPS) of $1.91. This result exceeded the Wall Street estimate of $1.73 per share by approximately 10.7%. On a GAAP basis, the company reported a net loss of $15.7 million, or $0.64 per diluted share, which was an improvement from a GAAP net loss of $23.8 million in the prior-year period.
Key financial highlights from the quarter include:
- Revenue: $540.7 million (reported) vs. $541.2 million (estimated)
- Non-GAAP EPS: $1.91 (reported) vs. $1.73 (estimated)
- Adjusted EBITDA: $98.2 million, compared to $105.5 million in Q4 2024.
- GAAP Gross Margin: Improved to 38% from 36% in the same quarter last year.
Market Reaction and Price Action
Following the earnings release, the stock’s after-hours trading showed minimal immediate movement, with a change of 0.0%. This muted initial reaction suggests the market had largely anticipated the results or is weighing the mixed signals—a top-line beat on declining sales against a stronger bottom-line performance.
Looking at recent performance, the stock has gained about 1.4% over the past week but is down approximately 3.5% over the last month, indicating some investor caution leading into the earnings report.
Divisional Performance and Strategic Shift
A review of the revenue breakdown reveals the primary driver behind the year-over-year sales decline. The company’s Vital Care product line, which historically included its IV Solutions business, saw revenue plummet from $190.0 million in Q4 2024 to $79.7 million in the recent quarter. This $110.3 million drop is directly attributed to the divestiture of the IV Solutions business, which was completed on May 1, 2025.
Excluding this divestiture, the company’s core businesses showed growth:
- Consumables revenue increased by 6.2% to $284.7 million.
- Infusion Systems revenue grew by 2.7% to $176.3 million.
This indicates that ICU Medical’s ongoing operations are performing steadily despite the headline revenue contraction from the strategic asset sale.
Fiscal 2026 Guidance vs. Analyst Expectations
Management provided its outlook for the full 2026 fiscal year, offering a point of comparison against existing analyst models. The company expects adjusted EPS in the range of $7.75 to $8.45. The midpoint of this guidance, $8.10, sits notably below the current analyst consensus estimate of $8.20 for the full year.
On the sales front, ICU Medical did not provide specific revenue guidance in the press release. Analysts, however, are currently modeling full-year 2026 sales of approximately $2.20 billion. For the upcoming first quarter of 2026, the consensus estimates are for revenue of $533.9 million and EPS of $1.82.
Summary and Outlook
ICU Medical’s fourth-quarter results reflect a company in transition. The strategic divestiture of the IV Solutions business has reshaped its revenue profile, leading to a significant reported sales decline that masks underlying growth in its core consumables and infusion systems divisions. The better-than-expected adjusted EPS demonstrates progress on profitability and cost management.
The initial guidance for 2026, with an EPS midpoint slightly below the current Street view, may contribute to a neutral to cautious near-term outlook from investors as they assess the company’s growth trajectory post-divestiture. The focus will likely shift to the company’s ability to drive organic growth from its remaining portfolio and leverage its improved operational efficiency.
For a detailed look at ICU Medical’s upcoming earnings dates and a comprehensive view of analyst estimates, you can review the information available on its earnings and estimates page.
Disclaimer: This article is for informational purposes only and does not constitute financial advice, nor does it recommend any investment actions. Investors should conduct their own research and consult with a qualified financial advisor before making any investment decisions.